EDIT off the bounce on low volume.
Nice support level at $20
Filled Gap up and Gap down.
If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels.
CRISPR got upgraded.
EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing approach more generally.
Licensing plays from one company to the other. No profit in the near term. Bump in stock off Crispr viral news.
Filled Gap up and Gap down.
If decent trading volume, long term investors or proponents to CAS-9 research will buy in at these support levels.
CRISPR got upgraded.
EDITAS holds patents that relate to the use of CRISPR-Cas9 in the cells of humans and other eukaryotes, while the UC Berkeley, Crispr, patents cover use of the gene-editing approach more generally.
Licensing plays from one company to the other. No profit in the near term. Bump in stock off Crispr viral news.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.